Clinical observation on acupoint application as an adjuvant therapy for treating cough after lung cancer surgery due to Qi deficiency and phlegm dampness
Article Sidebar
Main Article Content
Abstract
The Objective of this study was to investigate the therapeutic effect of acupoint application as an adjuvant therapy for treating cough after lung cancer surgery due to Qi deficiency and phlegm dampness. Fifty-one patients were completely random design divided into the treatment group (27 cases) and the control group (24 cases). The basic treatment of both groups was a Chinese medicine decoction of Xiaoqinglong combined with Sijunzi plus and minus.The treatment group was treated with acupoint application, while the control group was treated with blank acupoint application. The course of treatment was 14 days. The changes in cough symptoms, visual analog score (VAS) and peripheral blood serum cytokine levels were compared between the two groups before and after treatment. It was found that the effective rates of the treatment and control groups were 93.6% and 73.9% after 14 days of treatment, respectively, and the treatment group was significantly better than the control group (p < 0.01). VAS scores decreased in both groups after treatment, with a more significant decrease in the treatment group (p < 0.001). the peripheral blood cytokines interleukin-2r (IL-2r) and interleukin-6 (IL-6) improved in both groups after treatment, with statistically significant differences compared to pre-treatment, and the improvement was more pronounced in the treatment group (p < 0.001). In conclusion, acupoint application as an adjuvant was effective for treating cough after lung cancer surgery due to Qi-deficiency and phlegm-dampness, which could significantly improved the clinical symptoms of patients with cough after lung cancer surgery and effectively improve the quality of life of patients.
Article Details
References
Oncology Committee of Chinese Medical Association. Oncology Committee of Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2021 edition). National Medical Journal of China. 2021;101(23):1725-57. (in Chinese)
National Administration of Traditional Chinese Medicine. Criteria of diagnosis and therapeutic effects of diseases and syndromes in traditional Chinese medicine. Beijing: China Medical Science and Technology Press；2012. (in Chinese)
Chen G. Effects of Shenfu injection on chemotherapy-induced adverse effects and quality of life in patients with advanced non-small cell lung cancer：a systematic review and meta-analysis J Cancer Res Ther. 2018;14(12):S549-55.
Chu XX, Li LY. The role of interleukin in airway inflammation in chronic obstructive pulmonary disease. Journal of Hebei North University (natural science edition). 2014;30(05):110-3. (in Chinese)
Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, et al. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother. 2000;49(10):530-6.
Kuo SH, Chang DB, Lee YC, Lee YT, Luh KT. Tumour-infiltrating lymphocytes in non-small cell lung cancer are activated T lymphocytes. Journal of Asian Pacific Society of Respirology. 1998;3(1):55-9.
Yano T, Yoshino I, Yokoyama H, Fukuyama Y, Takai E, Asoh H, et al. The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer Journal. 1996;15(1):79-84.
Kawashima O, Kamiyoshihara M, Sakata S, Endo K, Saito R, Morishita Y. The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol. 2000;7(3):239-45.
Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol. Immunother. 2004;53:786-92.
Koh E, Iizasa T, Yamaji H, Sekine Y, Hiroshima K, Yoshino I, et al. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol. 2012;20(3):233-9.
Kita H, Shiraishi Y, Watanabe K, Suda K, Ohtsuka K, Koshiishi Y, et al. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?. Ann Thorac Cardiovasc Surg. 2011;17(5):454-60.
Zhou JJ, Qu ZX, Yan SP, Sun F, Whitsett JA, Shapiro SD, et al. Differential roles of STAT3 in the initiation and growth of lung cancer. Oncogene. 2015;34(29):3804-14.
Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413-8.
Qu ZX, Sun F, Zhou JJ, Li LW, Shapiro SD, Xiao GT. Interleukin-6 Prevents the Initiation but enhances the Pprogression of lung cancer. Cancer Res. 2015;75(16):3209-15.
